DR Congo Receives 70,000 Ervebo Vaccine Doses Amidst Spreading Bundibugyo Ebola Outbreak
The Democratic Republic of the Congo (DRC) has been allocated 70,000 doses of the Ervebo vaccine by the International Coordinating Group on Vaccine Provision (ICG) to combat an ongoing Ebola virus disease outbreak. This allocation follows a request from the DRC government. The Ervebo vaccine, known for its effectiveness against the Zaire ebolavirus, was initially developed for that strain. However, the current outbreak in the DRC is caused by the Bundibugyo strain, and the vaccine's efficacy against this specific strain is not yet confirmed. The World Health Organization (WHO) has acknowledged the allocation, noting that early laboratory and animal data suggest the vaccine might offer some protection against the Bundibugyo virus. The ICG's allocation includes 20,000 doses specifically for a Phase 3 clinical trial to assess the vaccine's impact on the Bundibugyo virus, while the remaining 50,000 doses are designated for frontline and health workers. This outbreak is described as the fastest Ebola outbreak i... 
